ResearcherColumbia UniversityNo recent work listed
Celine Yeh
Matched on ORCID iD 0000-0003-4663-4108; OpenAlex author ID A5022381803. Sources: OpenAlex.
Their work
- Papers
- 4
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 14
2021: 2 papers · 2022: none · 2023: 2 papers
Papers 4
- KRAS G12D inhibition in pancreatic cancer: Fas expression facilitates immune clearance. Co-author DOI 10.1016/j.devcel.2023.08.020↗
- Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regression Model to Pivotal Trial and Real-Wo… Co-author DOI 10.1093/oncolo/oyac217↗
- Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort and limited gain. Co-author DOI 10.1053/j.seminoncol.2021.01.001↗
- Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evaluation of tumor growth in Veterans. Co-author DOI 10.1053/j.seminoncol.2021.02.001↗
Closest collaborators
The 14 strongest of 14 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Susan Elaine Bates · 3 shared papers, 2021–2023 · strength 0.54
- Paper Two decades of research toward the treatment of locally advanced and metastatic pancreatic cancer: Remarkable effort an… DOI 10.1053/j.seminoncol.2021.01.001↗
- Paper Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regre… DOI 10.1093/oncolo/oyac217↗
- Paper Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evalu… DOI 10.1053/j.seminoncol.2021.02.001↗
- Wungki Park · 1 shared paper, 2023 · strength 0.31
- Rona D. Yaeger · 1 shared paper, 2023 · strength 0.31
- Thierry Conroy · 2 shared papers, 2021–2023 · strength 0.26
- Paper Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regre… DOI 10.1093/oncolo/oyac217↗
- Paper Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evalu… DOI 10.1053/j.seminoncol.2021.02.001↗
- Keith Magnus Sigel · 2 shared papers, 2021–2023 · strength 0.26
- Paper Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regre… DOI 10.1093/oncolo/oyac217↗
- Paper Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evalu… DOI 10.1053/j.seminoncol.2021.02.001↗
- Tito Fojo · 2 shared papers, 2021–2023 · strength 0.26
- Paper Tumor Growth Rate Informs Treatment Efficacy in Metastatic Pancreatic Adenocarcinoma: Application of a Growth and Regre… DOI 10.1093/oncolo/oyac217↗
- Paper Gemcitabine plus nab-paclitaxel versus FOLFIRINOX for unresected pancreatic cancer: Comparative effectiveness and evalu… DOI 10.1053/j.seminoncol.2021.02.001↗
- Yvonne M. Saenger · 1 shared paper, 2023 · strength 0.15
- Marc Ychou · 1 shared paper, 2023 · strength 0.15
- Gayle Jameson · 1 shared paper, 2023 · strength 0.15
- Rachael Ann Safyan · 1 shared paper, 2023 · strength 0.15
- Elizabeth M. Hecht · 1 shared paper, 2023 · strength 0.15
- John A. Chabot · 1 shared paper, 2023 · strength 0.15
- Gulam Abbas Manji · 1 shared paper, 2023 · strength 0.15
- Daniel D. Von Hoff · 1 shared paper, 2023 · strength 0.15
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.